Targeted delivery of antifungal drugs to treat mucormycosis
Targeted delivery of antifungal drug loaded liposomes to control mucormycosis
This study is testing a new way to deliver antifungal medicine directly to the cells that cause mucormycosis, a serious fungal infection, using tiny bubbles that carry the medication to help improve treatment for people with weakened immune systems while reducing side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10668509 on NIH RePORTER |
What this research studies
This research focuses on developing a new method to deliver antifungal drugs directly to the cells causing mucormycosis, a serious fungal infection. By using liposomes, which are tiny bubbles that can carry medication, the researchers aim to enhance the effectiveness of existing antifungal treatments while minimizing side effects. The approach targets the fungal cell wall and its protective layers, potentially improving treatment outcomes for patients with weakened immune systems. This innovative strategy addresses the urgent need for better therapies against invasive fungal diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with weakened immune systems, such as those with HIV/AIDS or those undergoing immunosuppressive therapies.
Not a fit: Patients with healthy immune systems or those not affected by mucormycosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce mortality rates and improve treatment efficacy for patients suffering from mucormycosis.
How similar studies have performed: Previous research has shown promise in using targeted drug delivery systems for antifungal treatments, indicating potential success for this novel approach.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Meagher, Richard Brian — University of Georgia
- Study coordinator: Meagher, Richard Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.